Please provide your email address to receive an email when new articles are posted on . Men with prostate cancer who received 5 mg twice-daily oxybutynin experienced ...

Vasomotor symptoms (VMS) including hot flashes are a common complaint among men undergoing androgen deprivation therapy (ADT) for prostate cancer. Although the symptoms are more widely associated with ...

Monique Addison, a former human resources professional in Pensacola, Florida, was in her mid-thirties when she began the transition to menopause, complete with hot flashes and night sweats. Also known ...

A phase 2 randomized, double-blind trial tested oxybutynin 2.5 mg BID and 5 mg BID versus placebo for six weeks in men on stable ADT with ≥28 weekly hot flashes. Dose-dependent efficacy was observed, ...